Piramal Pharma Limited

Who owns Piramal Pharma?
Piramal Pharma is publicly traded on NSE (PPLPHARMA) and BSE (543635). The Piramal Group (Ajay Piramal family) is the controlling shareholder. Carlyle Group holds approximately 15% following its 2020 investment.

What does Piramal Pharma do?
Piramal Pharma provides contract development and manufacturing (CDMO) services to global pharmaceutical companies, manufactures inhalational anesthetics and hospital generics (Piramal Critical Care), and sells consumer healthcare products in India (Lacto Calamine, i-pill, Saridon).

Is Piramal Pharma publicly traded?
Yes, Piramal Pharma is listed on NSE (PPLPHARMA) and BSE (543635). The company was demerged from Piramal Enterprises and listed in October 2022.

What is Piramal Pharma Solutions?
Piramal Pharma Solutions is the company's CDMO business, providing integrated contract development and manufacturing services to global pharmaceutical companies across the drug development lifecycle.

What consumer brands does Piramal Pharma own?
Piramal Pharma's consumer healthcare brands in India include Lacto Calamine (skin care), i-pill (emergency contraceptive), Saridon (headache relief), Littles (baby care), and Naturolax (laxative).

Piramal Pharma's origins trace to 1988 when Ajay Piramal's Piramal Group acquired Nicholas Laboratories India Limited, a pharmaceutical company. This acquisition marked the Piramal Group's entry into the pharmaceutical industry.

In 1993, Piramal Enterprises acquired Roche Products (India) Ltd from Hoffmann-La Roche, which was later renamed Piramal Healthcare Ltd. This acquisition added significant pharmaceutical manufacturing capabilities.

Piramal Healthcare expanded its CDMO capabilities through the acquisition of Hoechst Research Centre in Mulund (2000) and other facilities. The company built expertise in active pharmaceutical ingredient (API) manufacturing and drug formulation development.

In 2010, Piramal Healthcare made a landmark strategic decision, selling its domestic formulations business to Abbott Laboratories for approximately $3.72 billion. This was one of the largest pharmaceutical deals in Indian history. The sale allowed Piramal to focus on higher-margin CDMO services, critical care, and consumer healthcare.

Following the Abbott sale, Piramal expanded its CDMO business through acquisitions:

• Decision Point (2012): Acquired a US-based pharmaceutical consulting firm.
• Coldstream Laboratories (2012): Acquired a US-based CDMO.
• Ash Stevens (2012): Acquired a US-based API manufacturer.
• Torcan Chemical (2013): Acquired a Canadian API manufacturer.

In 2020, Carlyle Group invested approximately $490 million in Piramal Pharma for approximately 20% stake, providing capital for growth and validating the company's CDMO strategy.

In 2022, Piramal Enterprises was restructured, with the pharmaceutical and healthcare operations demerged as Piramal Pharma Limited and the financial services operations continuing as Piramal Enterprises. Piramal Pharma was listed on NSE and BSE in October 2022.

For fiscal year 2024 (ending March 2024), Piramal Pharma reported revenue of approximately 82 billion INR.

As a pharmaceutical manufacturer operating in regulated markets, Piramal Pharma is subject to oversight by the US FDA, UK MHRA, European EMA, and Indian CDSCO. The company's manufacturing facilities have been subject to routine FDA inspections.

Piramal Pharma's 2010 sale of its domestic formulations business to Abbott for $3.72 billion was a significant and somewhat controversial strategic decision, as it exited a large and growing Indian pharmaceutical market. The company subsequently reinvested the proceeds in financial services and CDMO businesses.